RBMXL1 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
K22-ub
LNTETNEkALETVFG
0 4
RBMXL1 (human) LNTETNEkALETVFG K22-ub
K30-ub
ALETVFGkYGRIVEV
0 1
RBMXL1 (human) ALETVFGkYGRIVEV K30-ub
T55-p
SRGFAFVtFEsPADA
0 1
RBMXL1 (human) SRGFAFVtFEsPADA T55-p
S58-p
FAFVtFEsPADAkDA
Upstream
0 30
Treatment
  • nocodazole
RBMXL1 (human) FAFVtFEsPADAkDA S58-p
K63-ub
FEsPADAkDAARDMN
0 10
RBMXL1 (human) FEsPADAkDAARDMN K63-ub
K72-ac
AARDMNGkSLDGkAI
0 7
RBMXL1 (human) AARDMNGkSLDGkAI K72-ac
K77-ub
NGkSLDGkAIKVEQA
0 2
RBMXL1 (human) NGkSLDGkAIKVEQA K77-ub
K86-m1
IKVEQATkPsFErGr
0 1
RBMXL1 (human) IKVEQATkPsFErGr K86-m1
S88-p
VEQATkPsFErGrHG
0 17
RBMXL1 (human) VEQATkPsFErGrHG S88-p
R91-m1
ATkPsFErGrHGPPP
0 3
RBMXL1 (human) ATkPsFErGrHGPPP R91-m1
R93-m1
kPsFErGrHGPPPPP
0 1
RBMXL1 (human) kPsFErGrHGPPPPP R93-m1
S102-p
GPPPPPRsRGPPrGF
0 1
RBMXL1 (human) GPPPPPRsRGPPrGF S102-p
R107-m1
PRsRGPPrGFGAGrG
0 2
RBMXL1 (human) PRsRGPPrGFGAGrG R107-m1
R113-m1
PrGFGAGrGGSGGTr
0 6
RBMXL1 (human) PrGFGAGrGGSGGTr R113-m1
R113-m2
PrGFGAGrGGSGGTr
0 1
RBMXL1 (human) PrGFGAGrGGSGGTr R113-m2
R120-m1
rGGSGGTrGPPSrGG
0 3
RBMXL1 (human) rGGSGGTrGPPSrGG R120-m1
R125-m1
GTrGPPSrGGHMDDG
0 39
RBMXL1 (human) GTrGPPSrGGHMDDG R125-m1
Y134-p
GHMDDGGySMNFNMs
Upstream
0 103
Treatment
  • U0126
RBMXL1 (human) GHMDDGGySMNFNMs Y134-p
S141-p
ySMNFNMssSrGPLP
Upstream
0 7
Treatment
  • nocodazole
RBMXL1 (human) ySMNFNMssSrGPLP S141-p
S142-p
SMNFNMssSrGPLPV
0 2
RBMXL1 (human) SMNFNMssSrGPLPV S142-p
R144-m1
NFNMssSrGPLPVkR
0 17
RBMXL1 (human) NFNMssSrGPLPVkR R144-m1
K150-ac
SrGPLPVkRGPPPRS
0 11
RBMXL1 (human) SrGPLPVkRGPPPRS K150-ac
S161-p
PPRSGGPsPKrSAPS
0 2
RBMXL1 (human) PPRSGGPsPKrSAPS S161-p
R164-m1
SGGPsPKrSAPSGLV
0 4
RBMXL1 (human) SGGPsPKrSAPSGLV R164-m1
R172-m1
SAPSGLVrSSSGMGG
0 6
RBMXL1 (human) SAPSGLVrSSSGMGG R172-m1
R180-m1
SSSGMGGrAPLSrGr
0 5
RBMXL1 (human) SSSGMGGrAPLSrGr R180-m1
R185-m1
GGrAPLSrGrDsyGG
0 8
RBMXL1 (human) GGrAPLSrGrDsyGG R185-m1
R187-m1
rAPLSrGrDsyGGPP
0 8
RBMXL1 (human) rAPLSrGrDsyGGPP R187-m1
S189-p
PLSrGrDsyGGPPrR
Upstream
0 15
Treatment
  • nocodazole
RBMXL1 (human) PLSrGrDsyGGPPrR S189-p
Y190-p
LSrGrDsyGGPPrRE
0 14
RBMXL1 (human) LSrGrDsyGGPPrRE Y190-p
R195-m1
DsyGGPPrREPLPSR
0 1
RBMXL1 (human) DsyGGPPrREPLPSR R195-m1
Y206-p
LPSRRDVyLsPRDDG
0 98
RBMXL1 (human) LPSRRDVyLsPRDDG Y206-p
S208-p
SRRDVyLsPRDDGyS
Upstream
0 155
Treatment
  • anti-CD3
  • metastatic potential
  • nocodazole
  • rapamycin
RBMXL1 (human) SRRDVyLsPRDDGyS S208-p
Y214-p
LsPRDDGySTkDSyS
0 135
RBMXL1 (human) LsPRDDGySTkDSyS Y214-p
K217-ub
RDDGySTkDSySsRD
0 8
RBMXL1 (human) RDDGySTkDSySsRD K217-ub
Y220-p
GySTkDSySsRDyPS
0 33
RBMXL1 (human) GySTkDSySsRDyPS Y220-p
S222-p
STkDSySsRDyPSSR
0 5
RBMXL1 (human) STkDSySsRDyPSSR S222-p
Y225-p
DSySsRDyPSSRDTR
0 12
RBMXL1 (human) DSySsRDyPSSRDTR Y225-p
Y234-p
SSRDTRDyAPPPRDY
0 63
RBMXL1 (human) SSRDTRDyAPPPRDY Y234-p
Y243-p
PPPRDYTyRDyGHss
0 13
RBMXL1 (human) PPPRDYTyRDyGHss Y243-p
Y246-p
RDYTyRDyGHssSRD
0 26
RBMXL1 (human) RDYTyRDyGHssSRD Y246-p
S249-p
TyRDyGHssSRDDyP
0 10
RBMXL1 (human) TyRDyGHssSRDDyP S249-p
S250-p
yRDyGHssSRDDyPs
0 3
RBMXL1 (human) yRDyGHssSRDDyPs S250-p
Y255-p
HssSRDDyPsRGYGD
Upstream
0 70
Treatment
  • U0126
RBMXL1 (human) HssSRDDyPsRGYGD Y255-p
S257-p
sSRDDyPsRGYGDRD
0 4
RBMXL1 (human) sSRDDyPsRGYGDRD S257-p
Y272-p
GYGRDRDysDHPsGG
Upstream
0 139
Treatment
  • Su11274
RBMXL1 (human) GYGRDRDysDHPsGG Y272-p
S273-p
YGRDRDysDHPsGGS
0 13
RBMXL1 (human) YGRDRDysDHPsGGS S273-p
S277-p
RDysDHPsGGSyRDS
Upstream
0 15
Treatment
  • dasatinib
  • nocodazole
RBMXL1 (human) RDysDHPsGGSyRDS S277-p
Y281-p
DHPsGGSyRDSyEsy
0 3
RBMXL1 (human) DHPsGGSyRDSyEsy Y281-p
Y285-p
GGSyRDSyEsyGNSr
0 137
RBMXL1 (human) GGSyRDSyEsyGNSr Y285-p
S287-p
SyRDSyEsyGNSrSA
0 28
RBMXL1 (human) SyRDSyEsyGNSrSA S287-p
Y288-p
yRDSyEsyGNSrSAP
0 62
RBMXL1 (human) yRDSyEsyGNSrSAP Y288-p
R292-m1
yEsyGNSrSAPLTrG
0 5
RBMXL1 (human) yEsyGNSrSAPLTrG R292-m1
R298-m1
SrSAPLTrGPPPSYG
0 1
RBMXL1 (human) SrSAPLTrGPPPSYG R298-m1
Y310-p
SYGGSSRyDDySSSR
0 21
RBMXL1 (human) SYGGSSRyDDySSSR Y310-p
Y313-p
GSSRyDDySSSRDGy
0 65
RBMXL1 (human) GSSRyDDySSSRDGy Y313-p
Y320-p
ySSSRDGyGGSRDsy
0 6
RBMXL1 (human) ySSSRDGyGGSRDsy Y320-p
S326-p
GyGGSRDsySSSRsD
Upstream
0 25
Kinase, in vitro:
  • AurB (human)
Treatment
  • nocodazole
RBMXL1 (human) GyGGSRDsySSSRsD S326-p
Y327-p
yGGSRDsySSSRsDL
0 1
RBMXL1 (human) yGGSRDsySSSRsDL Y327-p
S332-p
DsySSSRsDLySsCD
0 2
RBMXL1 (human) DsySSSRsDLySsCD S332-p
Y335-p
SSSRsDLySsCDRVG
0 20
RBMXL1 (human) SSSRsDLySsCDRVG Y335-p
S337-p
SRsDLySsCDRVGrQ
0 1
RBMXL1 (human) SRsDLySsCDRVGrQ S337-p
R343-m1
SsCDRVGrQErGLPP
0 1
RBMXL1 (human) SsCDRVGrQErGLPP R343-m1
R346-m1
DRVGrQErGLPPsVE
0 1
RBMXL1 (human) DRVGrQErGLPPsVE R346-m1
S351-p
QErGLPPsVErGYPS
Upstream
0 6
Treatment
  • ischemia
RBMXL1 (human) QErGLPPsVErGYPS S351-p
R354-m1
GLPPsVErGYPSSRD
0 1
RBMXL1 (human) GLPPsVErGYPSSRD R354-m1
S362-p
GYPSSRDsySSSSrG
0 1
RBMXL1 (human) GYPSSRDsySSSSrG S362-p
Y363-p
YPSSRDsySSSSrGA
0 1
RBMXL1 (human) YPSSRDsySSSSrGA Y363-p
R368-m1
DsySSSSrGAPrGAG
0 21
RBMXL1 (human) DsySSSSrGAPrGAG R368-m1
R368-m2
DsySSSSrGAPrGAG
0 2
RBMXL1 (human) DsySSSSrGAPrGAG R368-m2
R372-m1
SSSrGAPrGAGPGGS
0 17
RBMXL1 (human) SSSrGAPrGAGPGGS R372-m1
R372-m2
SSSrGAPrGAGPGGS
0 2
RBMXL1 (human) SSSrGAPrGAGPGGS R372-m2
R380-m1
GAGPGGSrSDRGGGR
0 7
RBMXL1 (human) GAGPGGSrSDRGGGR R380-m1